Home
Search
Placeholder Banner
Amicus Brief

BIO Submits Amicus Brief in Sandoz Inc. v. Amgen Manufacutring Inc. and Amgen Manufacturing Ltd v. Sandoz Inc. (U.S. Supreme Court)

March 17, 2017

BIO submitted an amicus brief in Sandoz Inc. v. Amgen Inc. and Amgen Manufacturing Limited, as well as Amgen Inc. and Amgen Manufacturing Limited v. Sandoz Inc., at the Supreme Court of the United States.

As one of the leading proponents for the creation of a biosimilar approval pathway that also maintains incentives for innovation, BIO has a strong interest in the proper implementation of this statutory scheme by the courts.

Related Resources
15-1039-15-1195-bsac-Biotechnology-Innovation-Organization 0
Download
15-1039-15-1195-bsac-Biotechnology-Innovation-Organization
BIO Amgen v. Sandoz Brief (SCOTUS)
Download
Discover More
BIO Files Amicus Brief in Delaware Supreme Court…
BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …
Learn more
BIO Files Amicus Briefs Supporting the Lawfulness…
On February 10, 2025, BIO filed an amicus brief in the U.S. District Court for the District of Columbia, supporting the lawfulness of plaintiff Eli Lilly's proposed 340B rebate model. The 340B Drug Pricing Program ("340B"), through which Medicaid…
Learn more
BIO Files Amicus Brief on FDA Orange Book Listing…
BIO filed an amicus brief in the U.S. Court of Appeals for the Federal Circuit urging rehearing of a case involving whether certain Teva Pharmaceuticals patents had been properly listed in FDA’s Orange Book (Approved Drug Products with Therapeutic…
Learn more